![Mark Chao](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Chao
Fondatore presso FORTY SEVEN, INC.
Posizioni attive di Mark Chao
Società | Posizione | Inizio | Fine |
---|---|---|---|
FORTY SEVEN, INC. | Fondatore | 01/01/2014 | - |
Corporate Officer/Principal | 01/01/2014 | - | |
Hepatx Corp.
![]() Hepatx Corp. Packaged SoftwareTechnology Services Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA. | Fondatore | 01/01/2015 | - |
TenSixteen Bio, Inc.
![]() TenSixteen Bio, Inc. BiotechnologyHealth Technology TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation. | Amministratore Delegato | 01/01/2021 | - |
Fondatore | 01/01/2021 | - | |
Foresite Labs LLC | Investitore di Private Equity | 01/01/2021 | - |
IconOVir Bio, Inc.
![]() IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Consulente / Consigliere | 01/12/2021 | - |
TigaTx, Inc.
![]() TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Consulente / Consigliere | 01/05/2020 | - |
Bioverge Funds Management LLC
![]() Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA. | Consulente / Consigliere | - | - |
Storia della carriera di Mark Chao
Precedenti posizioni note di Mark Chao
Società | Posizione | Inizio | Fine |
---|---|---|---|
GILEAD SCIENCES, INC. | Fondatore | - | - |
Corporate Officer/Principal | - | - |
Formazione di Mark Chao
Case Western Reserve University | Undergraduate Degree |
Stanford University School of Medicine | Doctorate Degree |
Stanford University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 12 |
Posizioni
Founder | 4 |
Consultant / Advisor | 3 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
Aziende private | 7 |
---|---|
Forty Seven, Inc.
![]() Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Hepatx Corp.
![]() Hepatx Corp. Packaged SoftwareTechnology Services Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA. | Technology Services |
TenSixteen Bio, Inc.
![]() TenSixteen Bio, Inc. BiotechnologyHealth Technology TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation. | Health Technology |
Foresite Labs LLC | |
IconOVir Bio, Inc.
![]() IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Health Technology |
TigaTx, Inc.
![]() TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Health Technology |
Bioverge Funds Management LLC
![]() Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA. | Finance |
- Borsa valori
- Insiders
- Mark Chao
- Esperienza